Genomic Valley Biotech Limited (BOM:539206)
India
· Delayed Price · Currency is INR 24.25
-1.27 (-4.98%)
At close: Apr 28, 2026
Genomic Valley Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 4.94 | 8.44 | 1.65 | 27.23 | 0.71 | 2.08 | Upgrade
|
| Revenue Growth (YoY) | -14.97% | 411.25% | -93.94% | 3758.23% | -66.09% | -75.42% | Upgrade
|
| Cost of Revenue | 2.02 | 2.02 | 0 | 15.86 | 0.02 | 1.3 | Upgrade
|
| Gross Profit | 2.92 | 6.42 | 1.65 | 11.37 | 0.68 | 0.78 | Upgrade
|
| Selling, General & Admin | 1.46 | 1.24 | 0.42 | 1.54 | 1.44 | 0.9 | Upgrade
|
| Other Operating Expenses | 0.9 | 0.79 | 1.06 | 1.04 | 2.44 | 1.07 | Upgrade
|
| Operating Expenses | 2.39 | 2.05 | 1.51 | 2.66 | 5.25 | 4.01 | Upgrade
|
| Operating Income | 0.53 | 4.37 | 0.14 | 8.71 | -4.56 | -3.23 | Upgrade
|
| Interest Expense | - | - | -0 | -0 | -0.43 | -1.79 | Upgrade
|
| Interest & Investment Income | 0.04 | 0.04 | 0 | 0.43 | 0.78 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.08 | - | 0.01 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 0.49 | 4.41 | 0.15 | 9.13 | -4.21 | -5.02 | Upgrade
|
| Other Unusual Items | - | - | - | -2.64 | 4.19 | - | Upgrade
|
| Pretax Income | 0.49 | 4.41 | 0.15 | 6.49 | -0.02 | -5.02 | Upgrade
|
| Income Tax Expense | 0.85 | 0.85 | -0 | 0.01 | 0.08 | 0.57 | Upgrade
|
| Net Income | -0.36 | 3.56 | 0.15 | 6.48 | -0.09 | -5.59 | Upgrade
|
| Net Income to Common | -0.36 | 3.56 | 0.15 | 6.48 | -0.09 | -5.59 | Upgrade
|
| Net Income Growth | - | 2245.53% | -97.66% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| Shares Change (YoY) | -3.56% | 0.24% | -0.70% | -1.79% | 1.91% | 0.41% | Upgrade
|
| EPS (Basic) | -0.12 | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 | Upgrade
|
| EPS (Diluted) | -0.12 | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 | Upgrade
|
| EPS Growth | - | 2240.00% | -97.64% | - | - | - | Upgrade
|
| Free Cash Flow | - | 0.18 | -0.2 | -7.79 | -21.29 | -0.95 | Upgrade
|
| Free Cash Flow Per Share | - | 0.06 | -0.07 | -2.55 | -6.84 | -0.31 | Upgrade
|
| Gross Margin | 59.09% | 76.08% | 99.78% | 41.75% | 96.53% | 37.44% | Upgrade
|
| Operating Margin | 10.65% | 51.78% | 8.56% | 31.99% | -646.85% | -155.37% | Upgrade
|
| Profit Margin | -7.29% | 42.19% | 9.20% | 23.81% | -13.24% | -268.67% | Upgrade
|
| Free Cash Flow Margin | - | 2.09% | -12.16% | -28.60% | -3017.82% | -45.45% | Upgrade
|
| EBITDA | 0.56 | 4.4 | 0.15 | 8.79 | -3.72 | -1.34 | Upgrade
|
| EBITDA Margin | 11.39% | 52.08% | 9.22% | 32.28% | - | -64.44% | Upgrade
|
| D&A For EBITDA | 0.04 | 0.03 | 0.01 | 0.08 | 0.84 | 1.89 | Upgrade
|
| EBIT | 0.53 | 4.37 | 0.14 | 8.71 | -4.56 | -3.23 | Upgrade
|
| EBIT Margin | 10.65% | 51.78% | 8.56% | 31.99% | - | -155.37% | Upgrade
|
| Effective Tax Rate | 172.81% | 19.33% | - | 0.09% | - | - | Upgrade
|
| Revenue as Reported | 4.9 | 8.48 | 1.67 | 27.65 | 1.55 | 2.11 | Upgrade
|
| Advertising Expenses | - | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.